KRAS and neoplasm: First, hematolymphopoietic neoplasias appeared to be largely driven by the amount of active Kras, as defined by RBD pull-down in both MEFs and lung tissue, as well as qRT-PCR of Kras target genes, transcriptome analysis, and RPPA analysis in lung tissue.